Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 1:256:117883.
doi: 10.1016/j.lfs.2020.117883. Epub 2020 Jun 1.

Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements

Affiliations
Review

Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements

Abhjieet Pandey et al. Life Sci. .

Abstract

The present pandemic of SARS-CoV-2 has been a tough task for the whole world to deal with. With the absence of specific drugs or vaccines against SARS-CoV-2, the situation is very difficult to control. Apart from the absence of specific therapies, the lack of knowledge about potential therapeutic targets and individual perception is adding to the complications. The present review describes the novel SARS-CoV-2 structure, surface proteins, asymptomatic and symptomatic transmission in addition to the genotype and phenotype of SARS-CoV-2 along with genetic strains and similarity between SARS, MERS and SARS-CoV-2. Therapeutic strategies such as inhibition of the endocytic pathway and suppressing RNA polymerase activity by metal ions, which could be quite beneficial for controlling COVID-19, are outlined. The drug repurposing for SARS-CoV-2 is discussed in detail along with therapeutic classes such as antivirals, antibiotics, and amino quinolones and their probable role in suppressing SARS-CoV-2 with reference to case studies. The ongoing clinical trials both with respect to drug repurposing and vaccines are summarized along with a brief description. The recent advancements and future perspective of ongoing research for therapy and detection of SARS-CoV-2 are provided. The review, in brief, summarizes epidemiology, therapy and the current scenario for combating SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors report no conflict of interest.

Figures

Unlabelled Image
Graphical abstract
Fig. 1
Fig. 1
Structure of SARS-CoV-2 (COVID-19).
Fig. 2
Fig. 2
Life cycle of SARS-CoV-2 (COVID-19).
Fig. 3
Fig. 3
Alternate pathways to control virus replication.
Fig. 4
Fig. 4
The chemical composition of chloroquine and hydroxychloroquine.
Fig. 5
Fig. 5
Schematic representation of chloroquine and hydroxychloroquine antiviral mechanisms.
Fig. 6
Fig. 6
Schematic depiction of convalescent plasma components and its mechanisms of action.

References

    1. Richman D.D., Whitley R.J., Hayden F.G. John Wiley & Sons; 2016. Clinical Virology.
    1. Chan-Yeung M., Xu R.-H. SARS: epidemiology. Respirology. 2003;(8 Suppl):S9–14. doi: 10.1046/j.1440-1843.2003.00518.x. - DOI - PMC - PubMed
    1. W.H. Organization Middle East respiratory syndrome coronavirus (MERS-CoV) 2016. http://www.who.int/emergencies/mers-cov/en Erişim Tarihi. 1 (n.d.)
    1. Wang N., Shi X., Jiang L., Zhang S., Wang D., Tong P., Guo D., Fu L., Cui Y., Liu X., Arledge K.C., Chen Y.-H., Zhang L., Wang X. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23:986–993. doi: 10.1038/cr.2013.92. - DOI - PMC - PubMed
    1. Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23:130–137. doi: 10.1111/resp.13196. - DOI - PMC - PubMed

MeSH terms